{"id":"W3043099150","doi":"10.1182/bloodadvances.2019001266","title":"Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"Moonshot Research and Development Program; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Takeda Oncology; Genentech; Health Resources and Services Administration; National Institutes of Health; MacroGenics; Omeros Corporation; Janssen Scientific Affairs; Mundipharma EDO; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; CTI Biopharma; bluebird bio; Cancer Moonshot; Chimerix; Medac; Jazz Pharmaceuticals; Janssen Biotech; HistoGenetics; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Celgene; Karyopharm Therapeutics; Atara Biotherapeutics; Actinium Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Biomedical Advanced Research and Development Authority; Amgen; CSL Behring; Bristol-Myers Squibb; Janssen Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Agios Pharmaceuticals; Sierra Oncology; Astellas Pharma US","keywords":"Medicine; Busulfan; Fludarabine; Melphalan; Internal medicine; Total body irradiation; Alemtuzumab; Hazard ratio; Transplantation; Myeloid leukemia; Gastroenterology; Surgery; Leukemia; Oncology; Hematopoietic stem cell transplantation; Chemotherapy; Cyclophosphamide; Confidence interval","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006038168,0.0003893525,0.0008523754,0.001282241,0.0001949376,0.0009511295,0.0005776712,0.0003930804,0.003482901],"category_scores_gemma":[0.006262215,0.0001379287,0.001013737,0.001567033,0.0003132579,0.0003857987,0.0005309987,0.0006171641,0.0004481146],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007722905,"about_ca_system_score_gemma":0.000940153,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001073975,"about_ca_topic_score_gemma":0.001491416,"domain_scores_codex":[0.9979114,0.0008853715,0.0004005573,0.0002382032,0.0004397938,0.0001246583],"domain_scores_gemma":[0.9976342,0.001045874,0.0004613765,0.0003508679,0.0003208538,0.0001868595],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.05360697,0.004289129,0.1451416,0.01030723,0.005962566,0.000708544,0.0004464352,0.001142052,0.008816657,0.001764729,0.006148852,0.7616652],"study_design_scores_gemma":[0.0147332,0.07599108,0.7076663,0.01423936,0.03156266,0.006948625,0.0009898042,0.003389887,0.01006196,0.001471463,0.1327157,0.0002300353],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7590439,0.2210614,0.003123445,0.001583822,0.0007055562,0.000918098,0.001481328,0.00006503798,0.01201752],"genre_scores_gemma":[0.9374505,0.05268105,0.003081132,0.00201941,0.001039433,0.0003611383,0.002549194,0.00004100224,0.0007771385],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006038168,"threshold_uncertainty_score":0.03193331,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0338867392681122,"score_gpt":0.3146726970560506,"score_spread":0.2807859577879384,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}